Table 4: Outcomes.

No antiplatelets
N = 379
Antiplatelets
N = 272
O.R. (95% CI)
P value

Hospital death n (%)98 (25.9)57 (21)0.76 (0.52–1.10)0.15
ICU death, n (%)46 (12.1)26 (9.6)0.77 (0.46–1.27)0.3
Hospital length of stay days, median (IQR)9.3 (5.5–16.9)8.9 (5.6–15.7)0.86
ICU length of stay days, median (IQR)2.5 (1.3–5.8)2.3 (1.3–4.7)0.31
ARDS/ALI, n (%)132 (34.8)57 (21)0.50 (0.35–0.71)<0.001
Invasive mechanical ventilation, n (%)158 (41.7)84 (30.9)0.62 (0.45–0.87)0.005
Length of invasive mechanical ventilation days, median (IQR)3.3 (1.3–8)3.5 (1.8–7)0.99
Noninvasive mechanical ventilation, n (%)68 (17.9)50 (18.4)1.03 (0.64–1.54)0.89
Length of noninvasive mechanical ventilation days, median (IQR)0.64 (0.2–1.8)1 (0.4–2)0.18
Acute kidney injury, n (%)299 (78.9)218 (80.2)1.08 (0.73–1.59)0.70
Stage of acute kidney injury
 Stage 1, n (%)126 (33.3)102 (37.5)NS
 Stage 2, n (%)63 (16.6)44 (16.2)NS
 Stage 3, n (%)110 (29)72 (26.5)NS
Renal replacement therapy, n (%)85 (22.4)53 (19.5)0.84 (0.57–1.23)0.37
Length of renal replacement therapy days, median (IQR)6 (3–11)4 (2–8)0.22

n: number, %: percentage, IQR: interquartile range, ARDS/ALI: acute respiratory distress syndrome/acute lung injury.